| | | Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Cohort Study | Anton Pozniak1, Gayathri Sridhar2, Lambert Assoumou1,3, Lionel Piroth4, Dominique Braun5, Carl Fletcher6, Leigh Ragone2,
Ajay Shah7, Jean van Wyk8, Vani Vannappagari2 | | | |
| | | E5 of a randomised switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N (Wisard study): Week 96 results | Graeme Moyle1, Lambert Assoumou2, Jean Michel Molina3, Fran Post4, Adrià Curran5, Stefano Rusconi6, Stephane De Wit7 ,Christoph Stephan8, François Raffi9, Margaret Johnson10, Mar Masia11, Jamie Vera12, Bryn Jones13, CarlFletcher 14, KellieMorris 14, Anton Pozniak 1, NEAT Foundation, WISARDstudygroup. | | | |
| | | 24 WEEK RANDOMISED STUDY OF SWITCH TO DTG/RPV IN SUBJECTS WITH HIV RNA <50C/ML AND ARCHIVED K103N | Graeme Moyle1, Lambert Assoumou2, Jean-Michel Molina3, Frank A. Post4, AdriàCurran5, Stefano Rusconi6, Stephane De Wit7, Christoph Stephan8, François Raffi9, Margaret Johnson10, Maria Del Mar Masia11, Jaime Vera12, Jacob Lowman13, Anton Pozniak14, for NEAT Foundation, WISARD study group1Chelsea | | | |
| | | Randomised study of switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N over 48 weeks | Graeme Moyle1, Lambert Assoumou2, Jean-Michel Molina3, FrankPost4, AdriàCurran5, Stefano Rusconi6, Stephane De Wit7, Christoph Stephan8, François Raffi9, Margaret Johnson10, Maria Del Mar Masia11, Jamie Vera12, Carl Fletcher13, Annie Duffy13, Kellie Morris13, Anton Pozniak1, for NEAT Foundation, WISARD study group. | | | |
WISARD | Clinical Trial | Paper | Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial | Graeme Moyle, Lambert Assoumou, Nathalie de Castro, Frank A Post, Adrian Curran, Stefano Rusconi, Stephane De Wit, Christoph Stephan,
François Raffi, Margaret Johnson, Mar Masia, Jaime Vera, Bryn Jones, Richard Grove, Carl Fletcher, Annie Duffy, Kellie Morris, Anton Pozniak,
for NEAT ID Foundation and the WISARD study group | Lancet HIV | | https://pubmed.ncbi.nlm.nih.gov/38417976/ |
Reprieve | Clinical Trial | Paper | Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) | Steven K.GrinspoonMDaKathleen V.FitchMSNaEdgar TurnerOvertonMDbCarl J.FichtenbaumMDcMarkella V.ZanniMDaJudith A.AbergMDdCarlosMalvestuttoMDeMichael T.LuMDjJudith S.CurrierMDfCraig A.SponsellerMDgMyronWaclawiwPhDhBeverlyAlston-SmithMDiKatharineCooper-ArnoldMPHhKarin L.KlingmanMDiPatriceDesvigne-NickensMDhUdoHoffmannMD, MPHjHeather J.RibaudoPhDkPamela S.DouglasMDlon behalf of the REPRIEVE Investigators | American Heart Journal | | https://www.sciencedirect.com/science/article/abs/pii/S0002870319300456?via%3Dihub |
Reprieve | Clinical Trial | Paper | Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination | Kathleen V. Fitch,Emma M. Kileel,Sara E. Looby,Markella V. Zanni,Laura R. Sanchez,Carl J. Fichtenbaum,Edgar T. Overton,Carlos Malvestutto,Judith A. Aberg,Karin L. Klingman,Beverly Alston-Smith,Judith Lavelle,Anne Rancourt,Sharlaa Badal-Faesen,Sandra Wagner Cardoso,Anchalee Avihingsanon,Sandesh Patil,Craig A. Sponseller,Kathleen Melbourne,Heather J. Ribaudo,Katharine Cooper-Arnold,Patrice Desvigne-Nickens,Udo Hoffmann,Pamela S. DouglasORCID Icon,Steven K. Grinspoon &on behalf of the REPRIEVE Investigators | HIV Research and Clinical Practice | | https://www.reprievetrial.org/successful-recruitment-of-a-multi-site-international-randomized-placebo-controlled-trial-in-people-with-hiv-with-attention-to-diversity-of-race-and-ethnicity-critical-role-of-central-coordination/ |
Reprieve | Clinical Trial | Paper | An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus | Edgar T Overton, Amy Kantor, Kathleen V Fitch, Paul Muntner, Khuanchai Supparatpinyo, Mosepele Mosepele, Lerato Mohapi, Sandra Wagner Cardoso, Sandesh Patil, Marcus V G de Lacerda, Grace McComsey, Judith A Aberg, Pamela S Douglas, Steven K Grinspoon, Heather Ribaudo, Christina M Wyatt | Journal of Infectious Diseases | | https://academic.oup.com/jid/article/222/Supplement_1/S41/5869457 |
Reprieve | Clinical Trial | Paper | Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial | Carl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, Edgar T Overton, Markella V Zanni, Carlos D Malvestutto, Judith A Aberg, Emma M Kileel, Kathleen V Fitch, Marije Van Schalkwyk, Nagalingeswaran Kumarasamy, Esteban Martinez, Breno Riegel Santos, Yvetot Joseph, Janet Lo, Sue Siminski, Kathleen Melbourne, Craig A Sponseller, Patrice Desvigne-Nickens, Gerald S Bloomfield, Judith S Currier, Udo Hoffmann, Pamela S Douglas, Steven K Grinspoon, REPRIEVE Investigators | Journal of Infectious Diseases | | https://academic.oup.com/jid/article/222/Supplement_1/S8/5869455 |
Reprieve | Clinical Trial | Paper | Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum | Laura M Smeaton, Emma M Kileel, Beatriz Grinsztejn, Edward M Gardner, Kate Starr, Melissa L Murry, Patrice Desvigne-Nickens, Beverly Alston-Smith, Myron A Waclawiw, Katharine Cooper-Arnold, José V Madruga, Shashi Sangle, Kathleen V Fitch, Markella V Zanni, Pamela S Douglas, Heather J Ribaudo, Steven K Grinspoon, Karin L Klingman | Journal of Infectious Diseases | | https://academic.oup.com/jid/article/222/Supplement_1/S31/5869453 |
Reprieve | Clinical Trial | Paper | Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction from the REPRIEVE Co-Principal Investigators | Steven K Grinspoon, Pamela S Douglas, Udo Hoffmann, Heather J Ribaudo | Journal of Infectious Diseases | | https://academic.oup.com/jid/article/222/Supplement_1/S1/5869454 |
Reprieve | Clinical Trial | Paper | Cardiovascular Risk and Health Among People with HIV Eligible for Primary Prevention: Insights from the REPRIEVE Trial | Pamela S Douglas, Triin Umbleja, Gerald S Bloomfield, Carl J Fichtenbaum, Markella V Zanni, Edgar T Overton, Kathleen V Fitch, Emma M Kileel, Judith A Aberg, Judith Currier, Craig A Sponseller, Kathleen Melbourne, Anchalee Avihingsanon, Flavio Bustorff, Vicente Estrada, Kiat Ruxrungtham, Maria Saumoy, Ann Marie Navar, Udo Hoffmann, Heather J Ribaudo, Steven Grinspoon on behalf of the REPRIEVE Investigators | Clinical Infectious Diseases | | https://academic.oup.com/cid/article/73/11/2009/6301132 |
